Quality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+)
Launched by TECHNISCHE UNIVERSITÄT DRESDEN ·
Trial Information
Current as of November 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study, called PROSa+, is exploring the quality of life and medical care of people in Germany who have survived sarcoma—a type of cancer—for five years or more. Researchers want to learn about survivors’ experiences, how they feel about their health and daily life, and their social and financial situations. The study will include surveys that participants can complete on paper or online, interviews with some participants to hear their stories in more detail, and information gathered from past sarcoma research.
People who have been diagnosed with sarcoma at least five years ago, regardless of whether their cancer is currently active or not, and who are adults of any gender, may be eligible to take part. If you join, you will be asked to fill out questionnaires about your health and life experiences, and some may be invited to share more through interviews. This study is not yet recruiting participants, but it aims to help improve understanding of the long-term needs of sarcoma survivors so that future medical care and support can be better tailored to them.
Gender
ALL
Eligibility criteria
About Technische Universität Dresden
Technische Universität Dresden (TU Dresden) is a leading research institution in Germany, renowned for its commitment to advancing scientific knowledge and innovation across various disciplines, including medicine and healthcare. As a clinical trial sponsor, TU Dresden leverages its cutting-edge research facilities and interdisciplinary expertise to facilitate the development of novel therapeutic interventions and improve patient outcomes. The university fosters collaboration among academic, clinical, and industry partners, ensuring rigorous adherence to ethical standards and regulatory requirements in the conduct of clinical research. Through its dedication to excellence and research-driven initiatives, TU Dresden plays a pivotal role in translating scientific discoveries into practical applications that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Martin Eichler, Dr.
Principal Investigator
TU Dresden & NCT/ UCC Dresden
Karen Steindorf, Prof. Dr.
Principal Investigator
DKFZ Heidelberg
Richard F. Schlenk, Prof. Dr.
Principal Investigator
NCT Heidelberg
Jens Jakob, Prof. Dr.
Principal Investigator
Sarcoma Center Mannheim
Uta Dirksen, Prof. Dr.
Principal Investigator
University Hospital, Essen
Markus Wartenberg
Principal Investigator
Deutsche Sarkom-Stiftung
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported